Study Summary
This trial tests if a daily dose of a drug can help children with peanut allergies become less sensitive to it over a year.
- Peanut Allergy
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Screening up to Month 14
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
DBV712 250 mcg
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
600 Total Participants · 2 Treatment Groups
Primary Treatment: DBV712 250 mcg · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 4 - 7 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| California | 100.0% |
What site did they apply to?
| DBV Investigative Site | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Frequently Asked Questions
Is enrollment being opened to individuals below the age of 45 for this experiment?
"This research is open to children aged between 4 and 7 years of age." - Anonymous Online Contributor
Does DBV712 250 mcg present any health risks to individuals?
"DBV712 250 mcg has been clinically evaluated for safety, and thus received a rating of 3. This signifies that the drug is in its third phase of testing with supporting evidence from previous trials to back up efficacy and side effect prevention or management." - Anonymous Online Contributor
To what extent is the capacity of this medical research limited?
"Indeed, the published information on clinicaltrials.gov attests that this research is actively enrolling participants. First made available on March 15th 2023, it seeks 600 volunteers from 49 medical sites." - Anonymous Online Contributor
Is there an opportunity to partake in this clinical study?
"This clinical trial is seeking 600 children aged between 4 and 7 who have been diagnosed with a peanut allergy. Participants must present an IgE level of more than 0.7 kUA/L, demonstrate a positive response to the skin prick test (SPT) with 6mm or greater in wheal diameter, and elicit an elicited dose (ED) of 100mg peanut protein during screening double blind placebo control food challenges (DBPCFC)." - Anonymous Online Contributor
Is there an opportunity for more individuals to join this trial?
"Data on clinicaltrials.gov verifies that this research endeavour is actively seeking out participants - the initial posting was made on March 15th 2023 and a recent update took place one day prior." - Anonymous Online Contributor
How many different sites are offering this clinical trial?
"Currently, this trial is operational at 49 sites spanning from Tucson to Los Angeles. To reduce travel-related issues, it's advantageous for prospective participants to pick a nearby location." - Anonymous Online Contributor